Abstract Library

#4461 Systemic anti-cancer therapy in gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC): Insights from National Cancer Registration and Analysis Service (NCRAS)

Introduction: ENETS advocates the use of platinum-based chemotherapy in combination with Etoposide as first-line chemotherapy in advanced GEP-NEC. Available retrospective evidence is from small studies.

Conference:

Presenting Author: Mortagy M

Authors: Mortagy M, El Asmar M, Paisey S, White B, Chandrakumaran K,

Keywords: Systemic anti-cancer therapy, Chemotherapy, GEP-NEC, NCRAS,

#4232 Aurora kinase A inhibition as a promising therapeutic strategy in ARID1A-mutated neuroendocrine carcinomas: First results of an in vitro and in vivo study

Introduction: Neuroendocrine carcinomas of the gastrointestinal tract (GEP-NEC) are rare but extremely aggressive tumor diseases with a 5-year survival rate of approximately 25%. The inactivating ARID1A mutation can be detected in approximately 40% of cases of GEP-NEC. Previous studies have shown that Aurora kinase A inhibition leads to selective synthetic lethality of ARID1A-deficient colorectal tumor cells.

Conference:

Presenting Author:

Authors: Viol F, Amin T, Sipos B, Fründt T, Smolkova B,

Keywords: Neuroendocrine Carcinoma, Mutation based Therapy, ARID1A, Aurora Kinase A,

#4018 Exploring the expression of DLL3 in gastroenteropancreatic neuroendocrine carcinomas and its potential diagnostic value

Introduction: The targeted treatment of DLL3 has attracted attention because of improving the prognosis of small cell lung cancer (SCLC), but the related research on DLL3 in GEP-NEC is relatively rare.

Conference:

Presenting Author:

Authors: Yin L, Jiang K, Zhao X, Hu Y, Lu M,

Keywords: DLL3, gastroenteropancreatic neuroendocrine carcinoma, targeted therapy, diagonsis,

#3704 Impact of surgical approach on short- and long-term outcomes in gastroenteropancreatic neuroendocrine carcinomas

Introduction: Complete resection is the cornerstone of curative-intent treatment for gastroenteropancreatic neuroendocrine carcinomas (GEP-NECs) without distant metastases. However, there is a paucity of data on the impact of recent advancements in minimally invasive surgery (MIS), such as the utilization of laparoscopic and robotic approaches, on GEP-NEC patients’ outcomes.

Conference:

Presenting Author: Chen Q

Authors: Chen Q, Rhodin K, Li K, Kanu E, Zani S,

Keywords: Gastroenteropancreatic neuroendocrine carcinoma, Minimally Invasive Surgery, Open resection, Laparoscopic resection, Robotic resection, Outcome,

#3133 Establishment of neuroendocrine neoplasms organoid biobank enables genotype-phenotype mapping

Introduction: Gastroentero-pancreatic (GEP) neuroendocrine neoplasm (NEN) that consists of neuroendocrine tumor (NET) and neuroendocrine carcinoma (NEC) is a lethal but under-investigated disease owing to its rarity. Incidence of this disease is recently increasing, and novel treatment is warranted. However, the establishment and application of GEP-NEN disease models have been limited.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Kawasaki K, Fujii M, Kudo A, Kanai T, Nakagawa H,

Keywords: organoids, CRISPR-Cas9, multi-omics analysis, gastrinoma, MiNEN,